SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
Healthcare
$17.95 +4.02%
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
52W Low $1.39High $9.51
Volume 35.53M
Average 7.79M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$28.39M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$86.30M
FY 2025 · Annual
+84.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| Deferred Income Tax | (239K) | (457K) | 0 | 0 | 0 |
| Stock-Based Compensation | 1.01M | 1.73M | 1.39M | 1.56M | 1.96M |
| Change in Working Capital | (7.62M) | 5.64M | 3.35M | (6.65M) | (4.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.51M) | 1.21M | 2.3M | (2.14M) | (535K) |
| Other Working Capital | (5.1M) | 4.43M | 1.04M | (4.51M) | (3.54M) |
| Other Non-Cash Items | 248K | 10.13M | (36.67M) | (30.95M) | 597K |
| Operating Cash Flow | (26.02M) | (23.81M) | (31.41M) | (35.4M) | (28.39M) |
| Capital Expenditures | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.01M | 23.99M | 22.23M | 46.16M | 86.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.07M | 85K | 90K | 594K | (527K) |
| Financing Cash Flow | 12.07M | 24.08M | 22.32M | 46.76M | 86.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.95M) | (4.23M) | (14.6M) | 11.36M | 57.91M |
| Free Cash Flow | (26.02M) | (28.31M) | (36.91M) | (35.4M) | (28.39M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$26.9M
+ D&A$0
+ Stock-Based Comp$2.0M
+ Deferred Tax$0
- Working Capital-$4.1M
+ Other Non-Cash$597.0K
= Operating Cash Flow-$28.4M
- Capex$0
= Free Cash Flow-$28.4M
Analysis
FY2025 free cash flow is -$28.4M. FCF conversion is 105.7% of net income. Operating cash flow was -$28.4M, with capex of $0. The largest bridge item is Working Capital at -$4.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
Does SLS generate free cash flow?
SELLAS Life Sciences Group, Inc. (SLS) generated -$28.39M of free cash flow in fiscal 2025.
How much operating cash flow does SLS produce?
Operating cash flow was -$28.39M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.